{"entity": "publication", "iuid": "9c03d18b02a44fd1b5f59f760bc5c51b", "timestamp": "2026-09-28T11:18:07.654Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/9c03d18b02a44fd1b5f59f760bc5c51b.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/9c03d18b02a44fd1b5f59f760bc5c51b"}}, "title": "Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling.", "authors": [{"family": "Mesmar", "given": "Fahmi", "initials": "F"}, {"family": "Dai", "given": "Bingbing", "initials": "B"}, {"family": "Ibrahim", "given": "Ahmed", "initials": "A"}, {"family": "Hases", "given": "Linnea", "initials": "L"}, {"family": "Jafferali", "given": "Mohammed Hakim", "initials": "MH"}, {"family": "Jose Augustine", "given": "Jithesh", "initials": "J"}, {"family": "DiLorenzo", "given": "Sebastian", "initials": "S"}, {"family": "Kang", "given": "Ya'an", "initials": "Y"}, {"family": "Zhao", "given": "Yang", "initials": "Y"}, {"family": "Wang", "given": "Jing", "initials": "J"}, {"family": "Kim", "given": "Michael", "initials": "M"}, {"family": "Lin", "given": "Chin-Yo", "initials": "CY"}, {"family": "Berkenstam", "given": "Anders", "initials": "A"}, {"family": "Fleming", "given": "Jason", "initials": "J"}, {"family": "Williams", "given": "Cecilia", "initials": "C", "orcid": "0000-0002-0602-2062", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/872c978997c74e89ae75efd90d592b42.json"}}], "type": "journal article", "published": "2019-12-00", "journal": {"title": "Cancer Med", "issn": "2045-7634", "volume": "8", "issue": "18", "pages": "7705-7719", "issn-l": "2045-7634"}, "abstract": "Despite advances in cancer therapeutics, pancreatic cancer remains difficult to treat and often develops resistance to chemotherapies. We have evaluated a bioavailable genistein analogue, AXP107-11 which has completed phase Ib clinical trial, as an approach to sensitize tumor cells to chemotherapy. Using organotypic cultures of 14 patient-derived xenografts (PDX) of pancreatic ductal adenocarcinoma, we found that addition of AXP107-11 indeed sensitized 57% of cases to gemcitabine treatment. Results were validated using PDX models in vivo. Further, RNA-Seq from responsive and unresponsive tumors proposed a 41-gene treatment-predictive signature. Functional and molecular assays were performed in cell lines and demonstrated that the effect was synergistic. Transcriptome analysis indicated activation of G-protein-coupled estrogen receptor (GPER1) as the main underlying mechanism of action, which was corroborated using GPER1-selective agonists and antagonists. GPER1 expression in pancreatic tumors was indicative of survival, and our study proposes that activation of GPER1 may constitute a new avenue for pancreatic cancer therapeutics.", "doi": "10.1002/cam4.2581", "pmid": "31568691", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6912054"}], "notes": [], "created": "2026-09-23T11:49:43.645Z", "modified": "2026-09-23T11:49:43.663Z"}